{"id":4596,"date":"2024-07-24T10:20:27","date_gmt":"2024-07-24T00:20:27","guid":{"rendered":"\/eu-uk\/?p=4596"},"modified":"2024-07-24T10:20:27","modified_gmt":"2024-07-24T00:20:27","slug":"orthocell-accelerates-global-market-expansion-of-striate-and-remplir-with-seven-new-regulatory-applications-either-in-progress-or-planned","status":"publish","type":"post","link":"\/eu-uk\/blog\/2024\/07\/24\/orthocell-accelerates-global-market-expansion-of-striate-and-remplir-with-seven-new-regulatory-applications-either-in-progress-or-planned\/","title":{"rendered":"Orthocell Accelerates Global Market Expansion of Striate+\u2122 and Remplir\u2122 With Seven New Regulatory Applications either in progress or planned"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">Orthocell has announced the accelerated market expansion of Striate+\u2122 and Remplir\u2122, with seven regulatory applications either in progress or planned for its medical device platform products.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The Company currently has two products gaining market traction \u2013 Striate+\u2122 for guided bone and tissue regeneration, and Remplir\u2122 for peripheral nerve repair.\u00a0 The global market opportunity for these products is estimated to be in excess of US$3 billion (circa A$4.5 billion), and Orthocell is targeting a 20% market share for both products.<\/span><\/p>\n<p><span style=\"font-weight: 400;\"><br \/>\n<\/span><b>Striate+<\/b><span style=\"font-weight: 400;\">\u2122<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">With Striate+\u2122 gaining excellent traction in the US, Europe\/UK and Australia, and approved in Canada, $OCC is accelerating market access into Brazil and Singapore with regulatory approvals anticipated within 6-12 months\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Orthocell is working with exclusive global distribution partner BioHorizons, to achieve further Striate+\u2122 regulatory approvals into multiple new large markets<\/span><\/li>\n<\/ul>\n<p><b>Remplir<\/b><span style=\"font-weight: 400;\">\u2122<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Remplir\u2122 is gaining strong traction in Australia with regulatory approval in Singapore anticipated within 6 months and the material US FDA approval expected within 9 months\u00a0\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">$OCC is accelerating market expansion of Remplir\u2122 into other new markets with regulatory applications in Canada, Thailand and EU\/UK planned for submission in the coming months<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Earlier this month, Orthocell announced record revenue in FY24, and a balance sheet of $20.6 million, placing it in a strong position to broaden its commercial footprint and grow product adoption and revenues in existing and new markets.<\/span><\/p>\n<p><a href=\"https:\/\/bit.ly\/OCC-Global-Expansion\"><span style=\"font-weight: 400;\">Click here to read the ASX release.<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Orthocell has announced the accelerated market expansion of Striate+\u2122 and Remplir\u2122, with seven regulatory applications either in progress or planned for its medical device platform products.<\/p>\n","protected":false},"author":2,"featured_media":4597,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-4596","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company-news"],"aioseo_notices":[],"_links":{"self":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/posts\/4596","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/comments?post=4596"}],"version-history":[{"count":1,"href":"\/eu-uk\/wp-json\/wp\/v2\/posts\/4596\/revisions"}],"predecessor-version":[{"id":4598,"href":"\/eu-uk\/wp-json\/wp\/v2\/posts\/4596\/revisions\/4598"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/media\/4597"}],"wp:attachment":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/media?parent=4596"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/categories?post=4596"},{"taxonomy":"post_tag","embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/tags?post=4596"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}